Disruptive Anti-Infective Technologies

ContraFect is developing first-in-class biologic therapies for life-threatening, drug-resistant infectious diseases.

News & Events

Sep 9, 2020

ContraFect to Present at the 2020 Cantor Global Virtual Healthcare Conference

Read More »

Aug 25, 2020

ContraFect Announces Funding Agreement with the Cystic Fibrosis Foundation

Read More »

See All News & Events »

About

ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus (MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa.


Learn More »

Media Coverage

Lysins Unlimited: Phages’ Secret Weapon

Genetic Engineering & Biotechnology News

View »

The Virtuous Side of Viruses

Scientific American

View »

Pfizer Takes Stake in a Biotech Company Called ContraFect

Barron’s

View »

Leadership

Our leadership team has a track record of creating shareholder value.

Roger J. Pomerantz, M.D., F.A.C.P.

Roger J. Pomerantz, M.D., F.A.C.P.

President, Chief Executive Officer and Chairman of the Board

Dr. Pomerantz was appointed ContraFect’s President, Chief Executive Officer and Chairman of the board of directors in April of 2019, prior to which he served as Vice Chairman of the Company’s board of directors sinc...

View Full Profile »
Cara Cassino, M.D.

Cara Cassino, M.D.

Chief Medical Officer and Executive Vice President of Research and Development

Dr. Cassino has over 20 years of experience as a clinician and executive in healthcare, including over 14 years of experience in pharmaceutical product development and over 20 successful regulatory submissions in the US and glo...

View Full Profile »
Michael Messinger, CPA

Michael Messinger, CPA

Chief Financial Officer

Mr. Messinger has more than 15 years of experience in finance, accounting and forecasting for clinical development. He served as Controller of Coelacanth Corporation prior to his role as Director of Finance for Lexicon Pharmace...

View Full Profile »
Natalie Bogdanos

Natalie Bogdanos

General Counsel, Corporate Secretary & Data Protection Officer

Ms. Bogdanos has more than 20 years of in-depth legal experience, across many areas of law including contract, intellectual property, licensing, regulatory, corporate governance, securities, litigation and data privacy. 14 of t...

View Full Profile »
Roger J. Pomerantz, M.D., F.A.C.P.

Roger J. Pomerantz, M.D., F.A.C.P.

President, Chief Executive Officer and Chairman of the Board

Dr. Pomerantz was appointed ContraFect’s President, Chief Executive Officer and Chairman of the board of directors in April of 2019, prior to which he served as Vice Chairman of the Company’s board of directors sinc...

View Full Profile »
Sol Barer, Ph.D.

Sol Barer, Ph.D.

Lead Director

Dr. Barer joined Celanese Research Company in 1974 and formed the Biotechnology Group that was spun out to form Celgene. Dr. Barer was Chairman and Chief Executive Officer from May 1, 2006 until June 16, 2010 and served as Exec...

View Full Profile »
Steven C. Gilman, Ph.D.

Steven C. Gilman, Ph.D.

Vice Chairman of the Board

Dr. Gilman has served on the board of directors since May 2015. He was Chief Executive Officer and Chairman of the board of directors from May 2015 until April 2019. Prior to ContraFect, he served as the Executive Vice Presiden...

View Full Profile »
Cary W. Sucoff

Cary W. Sucoff

Director

Mr. Sucoff has served as a member of our board of directors since May 2010. Mr. Sucoff has more than 30 years of securities industry experience encompassing supervisory, banking and sales responsibilities. He has participated i...

View Full Profile »
David N. Low, Jr.

David N. Low, Jr.

Director

Mr. Low has served as a member of our board of directors since April 2014. Mr. Low has worked as an investment banker since 1987, with broad investment and advisory experience in the life sciences, biotechnology and medical tec...

View Full Profile »
Michael J. Otto, Ph.D.

Michael J. Otto, Ph.D.

Director

Dr. Otto has served as a member of our board of directors since April 2014. Most recently, he was Chief Scientific Officer of Pharmasset from October 1999 until February 2012, when the company was acquired by Gilead Sciences. H...

View Full Profile »
Lishan Aklog, M.D.

Lishan Aklog, M.D.

Director

Dr. Aklog is Co-Founder, Chairman and Chief Executive Officer of PAVmed Inc. (Nasdaq: PAVM). Dr. Aklog has served as Executive Chairman of Lucid Diagnostics Inc. since its inception in 2018, as a co-founding Partner of both Pav...

View Full Profile »

Annaliesa Anderson, PhD, FAAM

Science & Technology Committee Observer

Dr. Anderson is an Observer on our Science & Technology Committee.  She has over 20 years of pharmaceutical research and development experience and is currently the Vice President and Chief Scientific Officer for Bacte...

View Full Profile »

Stock Information Data is 15 minutes delayed

ContraFect Corporation — Common Stock Nasdaq: CFRX
Price
Change
Market Cap
Volume
View Our

SEC Filings